Background and Aims: Infliximab and adalimumab are increasingly used to prevent postoperative recurrence in Crohn's disease patients. The impact of previous exposure to one or more anti-tumour necrosis factor [TNF] agents before surgery on the efficacy of anti-TNF therapy on postoperative recurrence is unknown. Methods: We performed a retrospective analysis of Crohn's disease patients who underwent surgical bowel resection with anastomosis and prophylactic treatment with anti-TNF therapy between January 2005 and June 2013. Results: A total of 57 consecutive Crohn's disease patients with bowel resection and anastomosis followed by prophylactic treatment with anti-TNF were included; 21 [37%] and 24 [42%] patients had a previous exposure to one and more than one anti-TNF agents, respectively; 39 patients [68%] had a surveillance colonoscopy. Cumulative rates of postoperative endoscopic recurrence at 2 years were 45.5% [26.6-69.6%] in patients exposed to two or more anti-TNFα as compared with 29.1% [11.5-48.1%] in patients exposed to one or to zero anti-TNFα before surgery [p = 0.07]. Cumulative rates of clinical recurrence at 1 year were 21.6% [9.6-44.4%] in patients exposed to two or more anti-TNFα as compared with 6.9% [1.8-25.1%] in patients exposed to zero or one anti-TNFα before surgery [p = 0.02]. Multivariable analysis identified smoking and previous exposure to two or more anti-TNFα as risk factors for Crohn's disease clinical or endoscopic postoperative recurrence (hazard ratio [HR] = 3.17; 95% confidence interval [CI]: 1.3-7.8, p = 0.01 and HR = 4.2; 95% CI: 1.8-10.2, p = 0.001, respectively).
Introduction
Crohn's disease [CD] is a chronic progressive and disabling condition. More than half of CD patients will require surgical bowel resection during their follow-up, for stenosis, perforation or inflammatory disease refractory to medical therapy. 1 After surgery and ileocolonic anastomosis, CD patients frequently present endoscopic relapse of the disease located on the neo-terminal ileum, leading ultimately to clinical recurrence and need for immunosuppressive therapy or treatment with anti-tumor necrosis factor [TNF]. [2] [3] [4] [5] [6] Prevention of postoperative recurrence with medical treatment is recommended in patients at high risk of postoperative recurrence based on previously identified risk factors. 7, 8 Thiopurines have modest efficacy in preventing CD endoscopic and clinical postoperative recurrence, with a high dropout level due to intolerance. 9, 10 Anti-TNF therapy is increasingly used to treat CD refractory to standard medications and to prevent postoperative CD recurrence. [11] [12] [13] [14] [15] [16] [17] Nevertheless, the impact of previous exposure to these drugs on the efficacy of infliximab or adalimumab in the prevention of postoperative recurrence is unknown in CD.
The aim of this retrospective study was therefore to evaluate the impact of previous exposure to one or more anti-TNF agents before surgery on their efficacy in preventing postoperative recurrence: the primary endpoint concerned endoscopic recurrence and the secondary endpoint was clinical postoperative recurrence in CD patients.
Materials and Methods

Patients
We conducted a retrospective cohort study of adult CD patients who underwent surgical bowel resection with intestinal anastomosis and received anti-TNF treatment for prevention of postoperative recurrence, in a French referral centre.
All the consecutive CD patients who underwent a surgical bowel resection from January 2005 to June 2013 in the digestive surgery department at the Lille University Hospital, which is a medical and surgical referral centre for 4 million people, were identified. Patients having had colonic or small bowel diversion, surgery for faecal stream diversion and anoperineal lesions, surgical reparation of stoma and anoperineal amputations, were excluded. When the surgical procedure comprised two or three surgical steps, we considered the ultimate continuity restoration to be the first day of postoperative setting. From the total of patients with bowel resection, we included in the study those who received in the 3 months following surgery a prophylactic treatment with anti-TNFα [infliximab, adalimumab or certolizumab pegol] for prevention of postoperative recurrence.
Patients showing signs of postoperative recurrence before prophylactic treatment, and those who had not received anti-TNFα in the postoperative period, were excluded. Patients who were included in therapeutic trials with a placebo were excluded.
Index surgery
Index surgery was defined as the first bowel resection preceding prophylactic treatment with anti-TNFα. The date of the index surgery, the type of surgery [colonic, small bowel or ileo-colonic resection], the indication for surgery [inflammation, stenosis, fistula or abscess], the length of the resection, the type of resection and the type of anastomosis performed were systematically recorded. Histological data regarding the characteristics of the resection margins [healthy, microscopically affected or macroscopically affected] and the presence of granulomas on the surgical sample, were also collected.
Postoperative treatment
Treatments received for prevention of CD postoperative recurrence were recorded: 5-aminosalicylates , thiopurines and anti-TNFα [infliximab, adalimumab and certolizumab pegol]. Metronidazole was not routinely used in our centre for prevention of postoperative recurrence; therefore no patient received metronidazole for prophylaxis in this study.
Assessment of recurrence
Endoscopic and clinical recurrences at 1 year after the index surgery and during the follow-up were recorded. Endoscopic recurrence was defined as a Rutgeerts score ≥ i2. When only a wireless capsule endoscopy [WCE] was available, endoscopic recurrence was defined as the judgment of the referring physician who read the capsule. 18, 19 As there is not a standardized definition of CD recurrence as assessed by WCE, in accordance with previous studies, 18 separate detection of ulcers, strictures or stenosis in the neoterminal ileum and/or anastomosis was considered compatible with CD recurrence. Clinical recurrence was defined as a clinically active CD assessed by the referring physician. Harvey-Bradshaw Index [HBI] was also retrospectively calculated using the medical chart of each patient.
We used as a primary endpoint the presence of clinical recurrence, and for the multivariable analysis the presence of any recurrence [endoscopic or clinical], owing to the small number of events.
Data collection
The entire data collection was carried out by the same investigator using a standardized form that was developed specifically for this study. Data were extracted from the computerized medical charts and anonymously reported in an Excel® database. A systematic analysis of the paper-based medical chart of every patient was done by the same investigator, to verify computerized information and collect missing data.
Statistical analysis
Quantitative variables were described by the median and the interquartile range. Qualitative variables were described by frequency and percentage. Eleven patients received a third round of anti-TNFα treatment and three patients received a fourth. For the third line, the reason for stopping anti-TNF was loss of response in 63% [7/11] , intolerance in only 27% [3/11] and other in 10% [1/11] . Overall, including all lines of anti-TNF, the main reasons for interrupting anti-TNF therapy were ineffectiveness in the majority of the cases [65%], followed by intolerance to treatment [14%] .
The median duration of anti-TNF treatment before surgery in CD patients only exposed to one anti-TNF before surgery was 11 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] months. The median duration of the anti-TNF treatment before surgery in CD patients exposed to multiple anti-TNF during the first, second and third line was 12 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] months, 12 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] months and 14 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] months, respectively.
Index surgery
The median age at the time of first resection was 30 [IQR: 25- [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] months in patients exposed to multiple anti-TNF and was not different from that of the patients exposed to only one anti-TNF (11 , p = 0.83). Indication of surgery in patients exposed to multiple anti-TNF was a penetrating disease in 50% [12/24] 
Prophylaxis of postoperative recurrence
The median time between surgery and anti- [11/14] . In contrast, postoperative treatment with adalimumab was more frequent in patients exposed to more than one anti-TNFα before surgery compared with patients exposed only to one anti-TNFα (86% [19/22] vs 43% [9/21] , respectively, p = 0.004).
Endoscopic recurrence
In all, 68% [39/57] of the patients had an endoscopic evaluation following surgery, with a median delay of 9 months [6] [7] [8] [9] [10] [11] [12] [13] . In the remaining patients, the causes for absence of endoscopic evaluation were patient's refusal to undergo the control colonoscopy [5/18] , loss of follow-up [3/18] , control by imaging [7/18] and pregnancy in one patient. Lastly, two patients did not have a colonoscopy for unknown reasons.
The cumulative rate of endoscopic recurrence, assessed by the Kaplan-Meier method, was 24.5% [95% CI: 13.6-41.9%] at 1 year and 37.8% [23.7-56 .6%] at 2 years. The Rutgeerts score was assessable for 33 patients; 21% [7/33] of the patients presented severe recurrence [Rutgeerts 3 and 4] . Six patients controlled by endoscopy did not have a Rutgeerts score, because of the non-visualization of the anastomosis during the colonoscopy [3/6] or the use of wireless capsule endoscopy [3/6] . Among the three patients evaluated with wireless capsule endoscopy, one had recurrence. Among patients without Rutgeerts evaluation and no capsule endoscopy, one patient had endoscopic signs of inflammation in the colon and clear sign of inflammation on imaging. Therefore, he was classified as an endoscopic recurrence.
Regarding previous exposure to anti-TNFα, only five patients among the 39 had no previous exposure to anti-TNFα; that is why we pooled patients exposed to zero and one anti-TNFα in following analyses. The cumulative rates of postoperative endoscopic recurrence at 1 and 2 years were 29.4% [14.4-54 .2%] and 45.5% [26.6-69 .6%], respectively, in patients exposed to two or more anti-TNFα as compared with 18.9 % [61-48.1%] and 29.1% [11.5-48 .1%], respectively, in patients exposed to one anti-TNFα or to zero anti-TNFα before surgery [ Figure 2 ]. However, the difference in cumulative endoscopic recurrence rates between patients exposed to two or more anti-TNFα and patients exposed to one or to zero anti-TNFα before surgery did not reach statistical significance [p = 0.07].
Clinical recurrence
Clinical recurrence was observed in 23% [13/57] Clinical recurrence was defined by physician global assessment which was prospectively evaluated in each patient. The HBI was not available prospectively but was calculated retrospectively. All patients with a clinical relapse evaluated by the referring physician during the follow-up had an HBI > 6 at the time of recurrence and patients with no recurrence had a statistically lower HBI compared with patients with clinical recurrence [1.13 ± 0.225 vs 8.55 ± 1.1, p < 0.001].
In the 39 patients for whom we had data on endoscopic evaluation, 21 
Factors associated with postoperative recurrence [clinical or endoscopic]
Factors associated with clinical or endoscopic recurrence are shown in Table 2 . In univariate analysis, only previous exposure to two or more anti-TNFα [HR = 3.23; 95% CI: 1.41-7.42, p = 0.006] was significantly associated with postoperative recurrence. 
Discussion
After ileocolonic resection for CD, clinical recurrence occurs in approximately one-third of the patients within the first 3 years and in 60% within 10 years; 25-33% of patients require additional surgery within 5 years. Thus prevention of postoperative recurrence in CD patients is a major challenge in clinical practice. There has been a recent focus on and several studies showing efficacy of anti-TNFα in this setting. 11, [13] [14] [15] 17, 20, 21 Nevertheless, most of the studies that investigated anti-TNFα to prevent postoperative recurrence in CD included a small number of patients exposed to multiple anti-TNFα before surgery. Therefore, none investigated the impact of administration of anti-TNFα before surgery. Recently, the POCER study 12 investigated the utility of endoscopic evaluation 6 months after intestinal resection for prevention of CD postoperative recurrence using adalimumab treatment in patients with high risk of relapse or intolerant to thiopurine. Patients who received adalimumab from the time of surgery and who had received any anti-TNFα in the 3 months preoperatively had a higher rate of endoscopic recurrence at 6 months compared with those who had not received anti-TNFα, without reaching statistically significant value [56%, n = 5/9 vs 5%, n = 1/19, p = 0.07].
In our study, a majority of patients [79%, n = 45] treated with anti-TNFα for prevention of postoperative recurrence had already received at least one anti-TNFα before surgery. Moreover, 42% of the patients had received two or more different anti-TNFα before index surgery. At 1 year, the cumulative endoscopic and clinical postoperative recurrence rates were 24.5 % [13.6%; 41.9%] and 13.0% [6.4%; 25.4%], respectively. In previous studies, with infliximab, Regueiro et al. 21 reported endoscopic and clinical recurrence at 1 year in 9 % and 0% of patients, respectively, Armuzzi et al.
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9% and 10%, and Yoshida et al. 17 21% and 13%, respectively. For adalimumab, Papamichael et al. 13 reported endoscopic and clinical recurrence rates in 26% and 12,5% of patients, respectively, where Savarino et al. 16 reported 6.3% and 12.5%, respectively. Our population was at high risk of recurrence, because 86% [49/57] of our patients had at least one risk factor for recurrence and 46% [26/57] had two or more risk factors. Another explanation could be a high rate of exposure [67%, 38/57] to infliximab before intestinal resection, as opposed to 30% and 54 % in the studies by Regueiro et 12 investigated the immediate preventive use of adalimumab in nine [32%] patients previously treated with infliximab.
We found an increased postoperative endoscopic recurrence in patients exposed to two or more anti-TNFα before surgery as compared with those exposed to one or none. Cumulative rates of postoperative endoscopic recurrence at 1 and 2 years were 29.4% [14.4-54 .2%] and 45.5% [26.6%-69.6%], respectively, in patients exposed to two or more anti-TNFα as compared with 18.9 % [6.1%-48.1%] and 29.1% [11.5%-48.1%], respectively, in patients exposed to one anti-TNFα or to zero anti-TNFα before surgery. However, the difference in cumulative rates of endoscopic recurrence between patients exposed to two or more anti-TNFα and patients [16.6-56 .3%], respectively, in patients exposed to two or more anti-TNFα as compared with 6.9% [1.8-25 .1%] and 11.2% [3.7-31 .0%] at 1 and 2 years, respectively, in patients exposed to zero or one anti-TNFα before surgery.
Predictive factors of CD postoperative recurrence which have been identified so far are smoking, previous history of surgery, extensive bowel resection, penetrating phenotype and perianal diseases. In patients who are candidates for receiving infliximab or adalimumab for prevention of postoperative recurrence, it would also be of interest to identify factors associated with the risk of anti-TNFα failure, in order to prevent futile treatment and discuss other therapies for patients that are predicted to be poor responders.
In our study population, we indeed confirmed that smoking was associated with a higher risk of postoperative recurrence, with am HR in multivariable analysis of 3. This result raises the question of the treatment of complicated CD [with abscesses or strictures] with anti-TNF. Indeed, surgery as first choice for such complications, without multiple expositions to anti-TNF, may avoid failure of these agents after surgery in the prevention of postoperative recurrence. However, to date we lack predictive factors of anti-TNF failure in stricturing or penetrating CD and we could not recommend systematic avoidance of medical therapy to favour surgery in these patients. A multicentre, prospective, observational cohort study from Getaid [the Creole Study], 22 investigating the efficacy of adalimumab in patients with CD and symptomatic small bowel stricture and only published as an abstract, describes a score which will predict failure or success of anti-TNF therapy in this setting and may help us to choose between anti-TNF and surgery. Nonetheless, if multiple exposures to previous anti-TNF are an independent predictor of poor outcomes in the postoperative setting, treatment with anti-TNF of complicated CD may be more indicated for naïve patients than for multiple anti-TNF experienced patients, keeping the second line of anti-TNF for the postoperative prophylaxis.
In our study, patients who required multiple lines of anti-TNF had mostly a progressive loss of response to several lines of anti-TNF therapy. This loss of efficacy may be explained by a more severe disease unresponsive to anti-TNF therapy because of development of non-TNF driven disease 23, 24 or appearance of resistance. 25 Since we did not have routinely assessed trough levels and antidrug antibodies in our patients, we could not elucidate the exact reason for loss of response. The use of multiple anti-TNF may be a surrogate marker of more severe, refractory disease before surgery. However, the lack of efficacy of anti-TNF to prevent postoperative recurrence in these patients after surgery, which removes all remaining disease, demonstrates that anti-TNF therapy may have been definitively overrun for whatever the reason [acquired resistance or transformation of the disease to a TNF-independent disease].
The strength of our study is, from a clinical perspective, the large number of CD patients under anti-TNFα treatment [n = 57] for prevention of postoperative recurrence, enabling us to detect factors associated with anti-TNFα treatment failure. Moreover, all patients were prospectively operated and followed in our centre with a restricted number of gastroenterologists performing clinical and endoscopic evaluation. Our study was able to confirm smoking as a predictive factor of clinical postoperative recurrence in CD, and the Rutgeerts score was also correlated with clinical postoperative recurrence during follow-up.
The limitations of our study are inherent in its retrospective character, that is the absence of a control group, and heterogeneity in data availability. Notably not all patients underwent endoscopic evaluation after surgery [n = 39/57], which resulted in missing data on endoscopic recurrence and prevented us from establishing a correlation between endoscopic and clinical recurrence during followup. However, clinical evolution of patient groups with and without colonoscopy was nevertheless comparable during follow-up. From a statistical point of view, one limitation is the small sample size that could be the reason for the non-significant result on endoscopic recurrence and that limited the ability to highlight associated factors. We also had to pool patients with one or none anti-TNFα before surgery, endoscopic and clinical recurrence rates for the associated factors, because there were not enough patients to analyse them separately. It seems to us that this choice was relevant, according to the fact that clinical recurrence was also used in previous studies on postoperative recurrence. 17, 26 In conclusion, in our study previous exposure to two or more anti-TNFα in CD patients who underwent intestinal resection was associated with a higher risk of anti-TNFα failure in preventing postoperative clinical recurrence. Future controlled prospective trials should take in to account exposure to all anti-TNFα before surgery when considering anti-TNFα for the prevention of CD postoperative recurrence. Previous acquired resistance should also be considered to avoid prescription of molecules that are going to be ineffective because of anti-drug antibodies. Last, considering that some CD patients are going to need medical treatment for prevention of postoperative recurrence in a situation where neither thiopurines nor anti-TNFα seem to be the right choice, we should seek alternative strategies. New biologics for CD, including anti-adhesion therapies or ustekinumab, should be tested in this situation.
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